51 terminated. 51 Phase 2, 8 Phase 3, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 51 | Terminated 51 |
| Phase 3 | 8 | Terminated 8 |
| Phase 1 | 4 | Terminated 4 |
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia Emraclidine 30 mg - Schizophrenia | Phase 2 | Terminated | AbbVie | 698 | 2022-09-01 | 2026-08-21 |
| Sodium Nitroprusside in Early Course Schizophrenia Sodium Nitroprusside, 5% Dextrose solution - Schizophrenia, Schizoaffective Disorder | Phase 2 | Terminated | Beth Israel Deaconess Medical Center | 1 | 2022-03-14 | 2025-12-30 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia Placebo, Luvadaxistat - Schizophrenia | Phase 2 | Terminated | Neurocrine Biosciences | 216 | 2021-12-07 | 2025-07-02 |
| A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase SEP-363856 50 mg, SEP-363856 75 mg, Placebo - Schizophrenia | Phase 2 / Phase 3 | Terminated | Sumitomo Pharma Co., Ltd. | 83 | 2021-03-29 | 2024-03-15 |
| Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment GWP42003-P, Placebo - Schizophrenia | Phase 2 | Terminated | Jazz Pharmaceuticals | 95 | 2020-08-18 | 2023-06-15 |
| Pharmacologic Modulation of Hippocampal Activity in Psychosis Levetiracetam 500 mg - Schizophrenia; Psychosis | Phase 2 | Terminated | Vanderbilt University Medical Center | 1 | 2020-05-11 | 2021-08-05 |
| A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia Oxytocin, Placebo - Schizophrenia | Phase 2 | Terminated | VA Office of Research and Development | 26 | 2020-01-13 | 2026-01-20 |
| Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms Lu AF11167 - Schizophrenia | Phase 2 | Terminated | H. Lundbeck A/S | 96 | 2019-04-22 | 2020-09-23 |
| ITI-007 (Lumateperone Tosylate) for Schizophrenia ITI-007 - Schizophrenia | Phase 2 | Terminated | New York State Psychiatric Institute | 4 | 2019-03-01 | 2021-11-04 |
| Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia Placebo, AVP-786 - Schizophrenia | Phase 2 / Phase 3 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 136 | 2019-02-15 | 2026-09-29 |
| Telmisartan Pilot Study on Treatment Resistant Schizophrenia Telmisartan Pill - Schizophrenia, Schizo Affective Disorder | Phase 2 | Terminated | Xiaoduo Fan | 6 | 2019-02-01 | 2022-03-02 |
| Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia Lu AF11167 (1-2 mg/day), Lu AF11167 (3-4 mg/day), Placebo - Schizophrenia | Phase 2 | Terminated | H. Lundbeck A/S | 168 | 2018-12-27 | 2020-09-23 |
| A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms RO6889450, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 2 | Terminated | Hoffmann-La Roche | 131 | 2018-12-04 | 2024-08-12 |
| Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia WSE, Placebo Oral Tablet - Schizophrenia | Phase 2 / Phase 3 | Terminated | Chengappa, K.N. Roy, MD | 47 | 2018-12-01 | 2024-10-08 |
| The Norwegian Prednisolone in Early Psychosis Study Prednisolone, Placebo - Schizophrenia and Related Disorders, Immune Suppression | Phase 2 | Terminated | Haukeland University Hospital | 12 | 2018-02-02 | 2022-08-01 |
| This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months BI 409306, Placebo - Schizophrenia | Phase 2 | Terminated | Boehringer Ingelheim | 264 | 2017-12-07 | 2025-05-14 |
| Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia Naltrexone, Bupropion, Placebo - Schizophrenia, Diabetes Mellitus, Type 2 | Phase 2 | Terminated | Yale University | 5 | 2017-06-01 | 2019-08-07 |
| Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults NaBen®, Placebo - Schizophrenia | Phase 2 / Phase 3 | Terminated | SyneuRx International (Taiwan) Corp | 280 | 2017-03-29 | 2024-05-24 |
| A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients Cannabidiol, Olanzapine, Placebo Cannabidiol - Schizophrenia | Phase 2 | Terminated | Central Institute of Mental Health, Mannheim | 150 | 2015-12-08 | 2024-12-27 |
| A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry Aripiprazole, Olanzapine, Paliperidone - Schizophrenia, Schizoaffective Disorder | Phase 2 | Terminated | Janssen Research & Development, LLC | 9 | 2015-05-01 | 2017-03-29 |
Showing 20 of 51. Sign in to see all of them.
Psychotic Disorders (12) · Cognitive Dysfunction (3) · Obesity (3) · Cognition Disorders (2) · Marijuana Abuse (2) · Mental Disorders (2) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Hypertension (1) · Memory Disorders (1) · Schizophrenia Spectrum and Other Psychotic Disorders (1) · Schizophrenia, Childhood (1) · Schizophrenia, Treatment-Resistant (1) · Smoking (1)
Schizophrenia Spectrum and Other Psychotic Disorders (50) · Mental Disorders (49) · Neurocognitive Disorders (5) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Body Weight (3) · Cognition Disorders (3) · Nutrition Disorders (3) · Nutritional and Metabolic Diseases (3) · Overnutrition (3) · Overweight (3) · Chemically-Induced Disorders (2) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Substance-Related Disorders (2)
Olanzapine (4) · Risperidone (3) · (R)-2-(4-(phenyl(3-(trifluoromethyl)phenyl)methyl)piperazin-1-yl)acetic acid (2) · 2-((4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy)methyl)quinoline (2) · Aripiprazole (2) · Dronabinol (2) · LY 2140023 (2) · Quetiapine Fumarate (2) · 1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-4-fluoro-benzyl)-(3-methyl-3-aza-bicyclo(3.1.0) hex-6-ylmethyl)amide (1) · ABT-126 (1) · ABT-925 (1) · AVE1625 (1) · Ashwagandha (1) · Atomoxetine Hydrochloride (1) · BI 409306 (1)
National Institute of Mental Health (NIMH) (3) · Pfizer (3) · AbbVie (2) · Amgen (2) · Denovo Biopharma LLC (2) · H. Lundbeck A/S (2) · New York State Psychiatric Institute (2) · SyneuRx International (Taiwan) Corp (2) · Abbott (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Beth Israel Deaconess Medical Center (1) · BioLineRx, Ltd. (1) · Birte Glenthoj (1) · Boehringer Ingelheim (1)
United States (38) · Bulgaria (5) · Canada (5) · Japan (5) · Poland (5) · Spain (5) · Taiwan (5) · Ukraine (5) · Czechia (3) · France (3) · Germany (3) · Hungary (3) · Puerto Rico (3) · Russia (3) · South Korea (3)
Alan Breier, MD (2) · Jose A Apud, M.D. (2) · Andrew Cutler, MD (1) · Arielle D. Stanford, MD (1) · Arnon Aharon, MD (1) · Beatrice Rendenbach-Mueller, PhD (1) · Birte Glenthoj, MD, DMSc. (1) · Brian A Fallon, MD (1)
PMID 27789188, PMID 28433500, PMID 35704951, PMID 21346607, PMID 23794107, PMID 25554563, PMID 25890643, PMID 26493637, PMID 27319970, PMID 28705532, PMID 32513294, PMID 36369028, PMID 39637767, PMID 42032293
2017 (1), 2019 (1), I01CX001761 (1)